Altasciences recently completed an important First-in-Human (FIH), Phase I, integrated adaptive clinical trial, including single and multiple ascending doses (SAD and MAD), Project Management, Bioanalysis, and Medical Writing, for sponsor Bellus Health.
Altasciences is excited to announce the completion of their laboratory expansion.
Altasciences today announced the completion of the acquisition of a preclinical testing business in Everett, Washington.
Altasciences is pleased to announce that Dr. Graham K. Wood, Chief R&D Officer at Altasciences, is presenting at a Continuing Legal Education program entitled Practical Implications of Decriminalized Marijuana for the Legal Practitioner on Wednesday, October 3.
Altasciences is pleased to welcome Dr. William J. Foster, MD, PhD, FRCSC, to the Altasciences family as Principal Investigator and Consultant on clinical trials.